The deal could bring in an additional $55 million, according to Smith & Nephew, based on financial performance.
The NovoStitch Pro device enables surgeons to repair arthroscopically horizontal, radial, complex, bucket handle and root tears, as well as vertical tears. Smith & Nephew noted that the device complements its own Fast-Fix 360 meniscal repair system, which is designed for vertical tears.
“NovoStitch Pro is an outstanding technology that addresses an unmet clinical need. We are delighted to add this device to our Sports Medicine portfolio and are looking forward to the opportunities that come with it,” Brad Cannon, president of Smith & Nephew’s sports medicine & ENT unit, said in prepared remarks.
“We are excited by the growth opportunities of the NovoStitch Pro at Smith & Nephew and are proud of the impact our technology has made in developing the meniscal repair market,” Ceterix founder & CMO Dr. Justin Saliman added.
Smith & Nephew first announced the deal in December last year.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.